| Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. | |
| | |
MedLine Citation:
|
PMID: 20569086 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To evaluate the effects of 1-year treatment with orlistat compared with placebo on different inflammatory parameters in type 2 obese diabetic patients. MATERIALS AND METHODS: Two hundred and fifty-four type 2 diabetic patients were randomized to take orlistat 120 mg three times a day or placebo for 12 months. We evaluated at baseline and after 3, 6, 9 and 12 months: leptin, tumor necrosis factor (TNF)-alpha, adiponectin (ADN), vaspin and high-sensitivity C-reactive protein (HS-CRP), body weight, waist circumference, body mass index (BMI), lipid profile, glycemic profile, fasting plasma insulin (FPI) and homeostasis model assessment insulin resistance index (HOMA-IR). RESULTS: Regarding inflammatory parameters, there was a significant improvement of ADN and TNF-alpha, and a faster decrease of leptin and HS-CRP in the orlistat group compared with the control group. We also recorded a significant reduction of body weight and BMI with orlistat, but not with placebo. A faster improvement of glycemic profile and FPI was obtained with orlistat compared with the controls. Also, there was a significant reduction of lipid profile with orlistat, not reached with placebo. CONCLUSIONS: Orlistat was more effective than placebo in ameliorating inflammatory parameters such as ADN and TNF-alpha, and anthropometric parameters. |
| | |
Authors:
|
Giuseppe Derosa; Pamela Maffioli; Sibilla A T Salvadeo; Ilaria Ferrari; Alessia Gravina; Roberto Mereu; Angela D'Angelo; Elena Fogari; Ilaria Palumbo; Sabrina Randazzo; Arrigo F G Cicero |
Related Documents
:
|
17327386 - Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. 15055476 - Serum leptin levels in acromegalic patients before and during somatostatin analogs ther... 16455776 - Differential role of sh2-b and aps in regulating energy and glucose homeostasis. 15202616 - Leptin, obesity and cardiovascular disease. 17142216 - Rosiglitazone versus bedtime insulin in the treatment of patients with conventional ora... 16059636 - Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cogn... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 11 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-20 Completed Date: 2010-11-02 Revised Date: 2012-04-09 |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 1971-82 Citation Subset: IM |
Affiliation:
|
University of Pavia, Department of Internal Medicine and Therapeutics, 27100 Pavia, Italy. giuseppe.derosa@unipv.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adiponectin
/
blood Anti-Obesity Agents / adverse effects, therapeutic use* Biological Markers / blood Blood Glucose / metabolism Body Mass Index Body Weight C-Reactive Protein / metabolism Diabetes Mellitus, Type 2 / drug therapy*, immunology, metabolism, physiopathology Double-Blind Method Female Humans Hypoglycemic Agents / therapeutic use* Inflammation Mediators / blood* Insulin / blood Insulin Resistance Italy Lactones / adverse effects, therapeutic use* Leptin / blood Lipids / blood Male Middle Aged Obesity / drug therapy*, immunology, metabolism, physiopathology Placebo Effect Serpins / blood Time Factors Treatment Outcome Tumor Necrosis Factor-alpha / blood Waist Circumference |
| Chemical | |
Reg. No./Substance:
|
0/ADIPOQ protein, human; 0/Adiponectin; 0/Anti-Obesity Agents; 0/Biological Markers; 0/Blood Glucose; 0/Hypoglycemic Agents; 0/Inflammation Mediators; 0/Insulin; 0/Lactones; 0/Leptin; 0/Lipids; 0/SERPINA12 protein, human; 0/Serpins; 0/Tumor Necrosis Factor-alpha; 9007-41-4/C-Reactive Protein; 96829-58-2/orlistat |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Niacin's role in the statin era.
Next Document: Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.